

# ForPatients

by Roche

Chronic Obstructive Pulmonary Disease (COPD)

## A Study Of <sup>12</sup>#XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications

**Trial Status**  
Terminated

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT04353661 GE42063

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will test whether daily use of azithromycin will reduce the rate of exacerbations and improve lung ventilation and perfusion assessed by XE-MRI. The sensitivity of XE-MRI to detect COPD progression will be compared with standard clinical assessment measures including standard lung function tests, 6 minute walk test, and patient reported quality of life.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

---

**NCT04353661 GE42063**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥40 Years

**Healthy Volunteers**  
No

---